About this item:

134 Views | 100 Downloads

Author Notes:

Marilyn J. Telen, MD, Box 2615 DUMC, Rm 333 MSRB1, Duke University Medical Center, Durham, NC 27710,TEL: 919 684 5378, FAX: 919 681 7688, marilyn.telen@duke.edu.

We would like to thank our subjects for participating in this study.

HE is a recipient of an American Society of Hematology HONORS Award.


Research Funding:

This work was supported by grants HL068959 and HL079915 from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH); and a Duke University Faculty Resident Research Grant.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology

Factors associated with survival in a contemporary adult sickle cell disease cohort


Journal Title:

American Journal of Hematology


Volume 89, Number 5


, Pages 530-535

Type of Work:

Article | Post-print: After Peer Review


In this study, the relationship of clinical differences among patients with sickle cell disease (SCD) was examined to understand the major contributors to early mortality in a contemporary cohort. Survival data were obtained for 542 adult subjects who were enrolled since 2002 at three university hospitals in the southeast United States. Subjects were followed up for a median of 9.3 years. At enrollment, clinical parameters were collected, including hemoglobin (Hb) genotype, baseline laboratory values, comorbidities, and medication usage. Levels of soluble adhesion molecules were measured for a subset of 87 subjects. The relationship of clinical characteristics to survival was determined using regression analysis. Median age at enrollment was 32 years. Median survival was 61 years for all subjects. Median survival for Hb SS and Sβ0 was 58 years and for Hb SC and Sβ+ was 66 years. Elevated white blood count, lower estimated glomerular filtration rate, proteinuria, frequency of pain crises, pulmonary hypertension, cerebrovascular events, seizures, stroke, sVCAM-1, and short-acting narcotics use were significantly associated with decreased survival. Forty-two percent of subjects were on hydroxyurea therapy, which was not associated with survival. SCD continues to reduce life expectancy for affected individuals, particularly those with Hb Sβ0 and SS. Not only were comorbidities individually associated with decreased survival but also an additive effect was observed, thus, those with a greater number of negative endpoints had worse survival (P<0.0001). The association of higher sVCAM-1 levels with decreased survival suggests that targeted therapies to reduce endothelial damage and inflammation may also be beneficial.

Copyright information:

© 2014 Wiley Periodicals, Inc.

Export to EndNote